---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-045633"
form_type: "8-K"
ticker: "RVRC"
cik: "0001839140"
company_name: "Revium Rx."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:22:04.011681+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Revium Rx appoints Amir Avraham permanent CEO, Shlomi Schwartzblat as Chairman

## Summary
- Appointed Amir Avraham as permanent CEO (was interim since May 2025), effective Feb 1, 2026.
- Monthly salary of NIS 55,000; eligible for annual discretionary bonus and one-time $50,000 bonus if $5M equity raised within 18 months.
- Option grant of 1,300,000 shares vesting from Feb 1, 2026; additional 300,000 upon $3M investments, and 300,000 upon M&A completion.
- Appointed Shlomi Schwartzblat as Director and Chairman of the Board, effective immediately, term through 2026 annual meeting.

## SEC filing metadata
- accession: 0001213900-26-045633
- form_type: 8-K
- ticker: RVRC
- cik: 0001839140
- company_name: Revium Rx.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1839140/000121390026045633/0001213900-26-045633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1839140/000121390026045633/ea0287042-8k_revium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-045633
- JSON: https://secwatch.observer/filing/0001213900-26-045633.json
- Plain text: https://secwatch.observer/filing/0001213900-26-045633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.